Industry Supported Session Programme

Breakfast symposia

Monday 27 May 07:30
NUTRACEUTICALS IN CONTROLLING LDL CHOLESTEROL

This breakfast symposium is organised and supported by Mylan

Invitation flyer 

Chair:
  • Maciej Banach
  • Alberico L. Catapano

Introduction

Alberico L. Catapano, Milano, Italy

Nutraceuticals in the guidelines

Alberico L. Catapano, Milano, Italy

Nutraceuticals in clinical practice

Maciej Banach, Lodz, Poland

Closing remarks

Maciej Banach, Lodz, Poland

Monday 27 May 07:31
RECENT STUDY UPDATES: MANAGING CHOLESTEROL IN HIGH RISK PATIENTS

This breakfast symposium is organised and supported by MSD

Chair:
  • Lale Tokgözoglu

The latest updates on the Familial Hypercholesterolemia Study Collaboration

Kausik Ray, London, UK

LDL-C guidelines targets & current treatment gaps

Anselm Gitt, Ludwigshafen, Germany

Improve-it lessons, how do they apply today?

Alberico L. Catapano, Milano, Italy

Roundtable discussion and Q&A - making sense of the latest data and what it means for high risk patients

Lale Tokgözoglu, Ankara, Turkey

Wednesday 29 May 07:30
EXPERT INSIGHTS: MANAGING CARDIOVASCULAR RISK

This breakfast symposium is organised and supported by Amarin

Chair:
  • Christy Ballantyne
  • Erik S. Stroes

Triglycerides and remnants hypothesis of cardiovascular risk

Borge G. Nordestgaard, Copenhagen, Denmark

Discussion

Inflammation hypothesis and the LoDoCo-trial

Arend Mosterd, Amersfoort, The Netherlands

Discussion

Educational symposia

Monday 27 May 13:15
PCSK9 INHIBITORS, FROM CLINICAL TRIALS TO THE REAL WORLD

This educational symposium is organised and supported by Amgen

Invitation flyer 

Chair:
  • Alberico L. Catapano

Lessons from real-world data

Kausik Ray, London, UK

Erik S. Stroes, Amsterdam, The Netherlands

Winfried März, Mannheim, Germany

The case for PCSK9I in very high-risk patients

Erik S. Stroes, Amsterdam, The Netherlands

Very high-risk patients: time for action

Kausik Ray, London, UK

The mandate for reducing residual CVD risk in patients with persistently elevated LDL-C

Alberico L. Catapano, Milano, Italy

Let’s get real: a discussion on LDL-C management 2019

Alberico L. Catapano, Milano, Italy

Special lectures

Tuesday 28 May 12:30
FIRE BUT NEVER FORGET

This special lecture is organised and supported by Alexion Pharma

Invitation flyer 

Chair:
  • M. John Chapman

Welcome and introduction

M. John Chapman, Paris, France

Right diagnosis for non-classical dyslipidemia

M. John Chapman, Paris, France

Unusual treatment for the unusual fatty liver

Vlad Ratziu, Paris, France

Q&A

M. John Chapman, Paris, France

Vlad Ratziu, Paris, France

Tuesday 28 May 13:45
TG LOWERING AND ITS IMPACT ON CVD REDUCTION: LDL-C IS NOT THE ONLY “USUAL SUSPECT”

This special lecture is organised and supported by Mylan

Chair:
  • Michal Vrablík
  • Alberto Zambon

Introduction

Michal Vrablík, Prague, Czech Republic

Presentation

Alberto Zambon, Padua, Italy

Q&A

Alberto Zambon, Padua, Italy

Michal Vrablík, Prague, Czech Republic

Tuesday 28 May 14:00
CHANGING THE FACE OF HoFH

This special lecture is organised and supported by Amryt Pharma

Chair:
  • Marcello Arca

Adapting management for better outcomes in HoFH – the story of case ‘C’

Jaimini Cegla, London, United Kingdom

The Pan-European picture

Marcello Arca, Rome, Italy

Q&A

Marcello Arca, Rome, Italy

Jaimini Cegla, London, United Kingdom